IL127733A0 - Chelating agents and their metal chelates for treating free radical induced conditions - Google Patents

Chelating agents and their metal chelates for treating free radical induced conditions

Info

Publication number
IL127733A0
IL127733A0 IL12773397A IL12773397A IL127733A0 IL 127733 A0 IL127733 A0 IL 127733A0 IL 12773397 A IL12773397 A IL 12773397A IL 12773397 A IL12773397 A IL 12773397A IL 127733 A0 IL127733 A0 IL 127733A0
Authority
IL
Israel
Prior art keywords
chelating agents
metal chelates
free radical
induced conditions
radical induced
Prior art date
Application number
IL12773397A
Other languages
English (en)
Original Assignee
Nycomed Imaging As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging As filed Critical Nycomed Imaging As
Publication of IL127733A0 publication Critical patent/IL127733A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Manufacture And Refinement Of Metals (AREA)
  • Semiconductor Lasers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
IL12773397A 1996-06-24 1997-06-24 Chelating agents and their metal chelates for treating free radical induced conditions IL127733A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9613182.6A GB9613182D0 (en) 1996-06-24 1996-06-24 Method
PCT/GB1997/001722 WO1997049409A1 (en) 1996-06-24 1997-06-24 Chelating agents and their metal chelates for treating free radicals induced conditions

Publications (1)

Publication Number Publication Date
IL127733A0 true IL127733A0 (en) 1999-10-28

Family

ID=10795775

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12773397A IL127733A0 (en) 1996-06-24 1997-06-24 Chelating agents and their metal chelates for treating free radical induced conditions

Country Status (14)

Country Link
US (2) US6258828B1 (da)
EP (2) EP0910360B1 (da)
JP (2) JP4162263B2 (da)
CN (2) CN1228694A (da)
AT (2) ATE228361T1 (da)
AU (2) AU720621B2 (da)
BR (1) BR9709942A (da)
CA (2) CA2259150A1 (da)
DE (2) DE69716104T2 (da)
GB (1) GB9613182D0 (da)
IL (1) IL127733A0 (da)
NO (2) NO985917L (da)
NZ (2) NZ333315A (da)
WO (2) WO1997049390A1 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001527072A (ja) * 1997-12-23 2001-12-25 ニユコメド・イメージング・アクシエセルカペト 一酸化窒素を放出するキレート化剤およびその治療上の使用
GB9727224D0 (en) * 1997-12-23 1998-02-25 Nycomed Imaging As Method
KR101353140B1 (ko) 1999-10-01 2014-01-20 디엠아이 바이오사이언시스, 인크 금속 결합 화합물 및 그의 용도
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
FR2823977B1 (fr) * 2001-04-26 2006-12-01 Univ Rene Descartes Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US20040038904A1 (en) * 2002-05-21 2004-02-26 Angela Ogden Method of treating multiple sclerosis
FR2863892B1 (fr) * 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
WO2005102359A1 (en) 2004-04-22 2005-11-03 Celator Pharmaceuticals, Inc. Liposomal formulations of anthracycline agents and cytidine analogs
BRPI0615265A8 (pt) 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
JP5484352B2 (ja) 2007-12-14 2014-05-07 プレッドファルマ・アーベー 癌の治療に使用するための化合物
CN102481295A (zh) * 2009-07-06 2012-05-30 普莱制药公司 利用锰配合物化合物与所述化合物之非锰配合物形式的组合的药物组合物和治疗方法
EP2707030B1 (en) 2011-05-09 2020-02-19 Mayo Foundation For Medical Education And Research Cancer treatments
US9187509B2 (en) 2012-01-05 2015-11-17 Pled Pharma AB Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment
EP3967306A1 (en) 2012-10-01 2022-03-16 Mayo Foundation for Medical Education and Research Cancer treatments
BR112015009963A2 (pt) 2012-11-02 2017-07-11 Pledpharma Ab uso de compostos para a preparação de composições farmacêuticas para o tratamento de câncer
US20160250351A1 (en) 2014-06-13 2016-09-01 Mayo Foundation For Medical Education And Research Treating Lymphomas
KR20210125603A (ko) 2014-06-16 2021-10-18 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 골수종의 치료
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
US11571469B2 (en) 2016-01-07 2023-02-07 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
EP3413874A4 (en) 2016-02-12 2020-01-22 Mayo Foundation for Medical Education and Research TREATMENTS FOR BLOOD CANCER
AU2017238119A1 (en) * 2016-03-21 2018-10-11 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
WO2017165439A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
WO2018045238A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Methods and compositions for targeting t-cell cancers
ES2937291T3 (es) 2016-09-01 2023-03-27 Mayo Found Medical Education & Res Composiciones de agentes que se unen al transportador PD-L1 y métodos de uso de las mismas para tratar cánceres
CN109890422A (zh) 2016-09-06 2019-06-14 梅约医学教育与研究基金会 紫杉醇-白蛋白-结合剂组合物及使用和制备该组合物的方法
CN109843924A (zh) 2016-09-06 2019-06-04 梅约医学教育与研究基金会 治疗表达pd-l1的癌症的方法
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES444380A1 (es) * 1976-01-16 1977-06-16 Gosalvez Mario Un procedimiento para preparar derivados metalicos antraci- clinicos.
US4935518A (en) * 1987-05-08 1990-06-19 Salutar, Inc. Manganese(II), chelate contrast agents derived from N,N'-bis-(pyridoxal ethylene diamine-N,N')-diacetic acid and derivatives thereof
US4842845A (en) * 1987-05-08 1989-06-27 Salutar, Inc. Radioactive metal chelates for dipyridoxyl phosphate
US5223243A (en) * 1987-05-08 1993-06-29 Salutar, Inc. Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents
US6204259B1 (en) * 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

Also Published As

Publication number Publication date
CN1228703A (zh) 1999-09-15
AU3268897A (en) 1998-01-14
NO985916D0 (no) 1998-12-17
EP0910360B1 (en) 2002-11-27
DE69716104T2 (de) 2003-05-28
NO985917D0 (no) 1998-12-17
JP2000513351A (ja) 2000-10-10
EP0936915B1 (en) 2002-10-02
JP2000514044A (ja) 2000-10-24
NO985917L (no) 1999-01-25
DE69717447D1 (de) 2003-01-09
CA2258299A1 (en) 1997-12-31
NZ333357A (en) 2000-08-25
AU3268997A (en) 1998-01-14
ATE225178T1 (de) 2002-10-15
CA2259150A1 (en) 1997-12-31
NO985916L (no) 1999-01-25
US6147094A (en) 2000-11-14
AU720570B2 (en) 2000-06-08
US6258828B1 (en) 2001-07-10
WO1997049390A1 (en) 1997-12-31
NZ333315A (en) 2000-07-28
GB9613182D0 (en) 1996-08-28
DE69716104D1 (de) 2002-11-07
EP0936915A1 (en) 1999-08-25
DE69717447T2 (de) 2003-09-11
AU720621B2 (en) 2000-06-08
JP4359651B2 (ja) 2009-11-04
BR9709942A (pt) 1999-08-10
ATE228361T1 (de) 2002-12-15
EP0910360A1 (en) 1999-04-28
JP4162263B2 (ja) 2008-10-08
WO1997049409A1 (en) 1997-12-31
CN1228694A (zh) 1999-09-15

Similar Documents

Publication Publication Date Title
IL127733A0 (en) Chelating agents and their metal chelates for treating free radical induced conditions
AU1770299A (en) Nitric oxide releasing chelating agents and their therapeutic use
MY135985A (en) Antitumor synergistic composition.
MXPA04004555A (es) Dexrazoxano para tratamiento de cardiotoxicidad inducida por antitumor.
EP1229934A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER BY MEANS OF IMMUNO-CONJUGATES AND CHEMOTHERAPEUTIC AGENTS
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
IL129949A (en) Use of minesulide in the preparation of pharmaceutical compositions for treating neurodegenerative conditions
IL131349A0 (en) Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
AU2001275228A1 (en) Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor
CZ2000531A3 (en) Method of prevention or therapy of estrogen-dependent diseases and disorders
TW362971B (en) Pharmaceutical composition and kit for treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and a S-phase or M-phase specific anti
MY136610A (en) Combined preparations comprising morpholine anthracyclines and platinum derivatives
PT1109571E (pt) Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos
WO1998036730A3 (de) Zubereitungen für die behandlung von rosacea
MXPA02005045A (es) Preparaciones farmaceuticas que contiene agentes citostaticos y aceptores de electrones para el tratamiento de cancer.
MX9601031A (es) Composicion farmaceutica para el tratamiento y prevencion del cancer de prostata.
CA2294243A1 (en) Novel cyanoaziridines for treating cancer
GB2312375B (en) Agents for treatment of cancer
EP0793499A4 (en) METHOD AND MEANS FOR REDUCING TUMOR DEVELOPMENT BY MEANS OF A COMBINATION OF A TAXAN COMPOUND AND A TELLUR AND / OR SELENIUM COMPOUND
ES2195922T3 (es) Composicion sinergica que comprende derivados de daunorrubicina y compuestos antimetabolitos.
WO1998046193A3 (en) Synergistic method for treating a neoplasm
HK1021135A (en) Chelating agents and their metal chelates for treating free radicals induced conditions
UA41376C2 (uk) ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЛІКУВАННЯ АНДРОГЕННОЇ АЛОПЕЦІЇ ІНГІБІТОРАМИ 5-<font face="Symbol">a</font>-РЕДУКТАЗИ
MX9800697A (es) Uso de glicosidos de calendula para el tratamiento de psoriasis.
UA36341A (uk) Спосіб лікування запальних процесів навколозубних тканин